Interní Med. 2019; 21(3): 142-148 | DOI: 10.36290/int.2019.021

Dangerous multiresistant bacteria "superbugs" in contemporary medicine

prof. MUDr. Milan Kolář, Ph.D.
Ústav mikrobiologie FNOL a LF UP v Olomouci

In this review article the term „superbugs“ is defined and clinically significant multiresistant bacteria are characterized.

Keywords: bacteria, antibiotics, resistance, superbugs

Published: June 30, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolář M. Dangerous multiresistant bacteria "superbugs" in contemporary medicine. Interní Med. 2019;21(3):142-148. doi: 10.36290/int.2019.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kolář M. Interpretace bakteriální citlivosti/rezistence k antibiotikům. Klin Mikrobiol Inf Lék 2016, 22: 105-109.
    2. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-ß-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51: 1987-1994. Go to original source... Go to PubMed...
    3. Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012, 91: 115-121. Go to original source... Go to PubMed...
    4. Herkel T, Uvizl R, Adamus M, et al. Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Papers 2016, 160: 448-455. Go to original source... Go to PubMed...
    5. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18: 268-281. Go to original source... Go to PubMed...
    6. Urbánek K, Kolář M, Strojil J, et al. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol Drug Safety 2005, 14: 741-745. Go to original source... Go to PubMed...
    7. Urbánek K, Kolář M, Lovečková Y, Strojil J, Šantavá L. Influence of 3rd generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Therap 2007, 32: 403-408. Go to original source... Go to PubMed...
    8. Kolář M, Urbánek K, Látal T. Antibiotic selective pressure and development of bacterial resistance. International J Antimicrob Agents 2001, 17: 357-363. Go to original source... Go to PubMed...
    9. Kesselová M, Kolář M, Sauer P, et al. Molekulárně-biologická analýza ESBL-pozitivních kmenů Klebsiella pneumoniae na novorozeneckém oddělení Fakultní nemocnice Olomouc. Klin Mikrobiol Inf Lék 2005, 11: 20-24.
    10. Asensio A, Alvarez-Espejo T, Fernandes-Crehuet J, et al. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. Euro Surveill 2011, 16: pii=19983. Go to original source... Go to PubMed...
    11. Htoutou Sedláková M, Vojtová V, Hanulík V, et al. Rezistence enterobakterií k vybraným antibiotikům v souvislosti s jejich spotřebou. Klin Farmakol Farmacie 2012, 26: 61-66.
    12. Ambler RP. The structure of ?-lactamases. Philos Trans R Soc Lond B Biol Sci 1980, 289: 321-331. Go to original source... Go to PubMed...
    13. Bush K, Jacoby GA. Updated functional classification of ?-Lactamases. Antimicrob Agents Chemother 2010, 54: 969-976. Go to original source... Go to PubMed...
    14. Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012, 91: 115-121. Go to original source... Go to PubMed...
    15. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 2013, 54: 799-806. Go to original source... Go to PubMed...
    16. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum ?-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011, 30:3 55-360. Go to original source... Go to PubMed...
    17. Kolář M, Htoutou Sedláková M, Pudova P, et al. Incidence of fecal Enterobacteriaceae producing broad-spectrum beta-lactamases in patients with hematological malignancies. Biomed Papers 2015, 159: 100-103. Go to original source... Go to PubMed...
    18. Mlynarcik P, Kolar M. Molecular mechanisms of polymyxin resistance and detection of mcr genes. Biomed Papers 2019, 163: 28-38. Go to original source... Go to PubMed...
    19. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016, 16: 161-168. Go to original source... Go to PubMed...
    20. Gao R, Hu Y, Li Z, et al. Dissemination and mechanism for the mcr-1 colistin resistance. PLoS Pathog 2016, 12: e1005957. Go to original source... Go to PubMed...
    21. Gelbíčová T, Baráková A, Florianová M, Karpíšková R. Nález Acinetobacter baumannii s rezistencí ke kolistinu s genem mcr-4. Klin Mikrobiol Inf Lék 2019, 25: 4-6.
    22. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia 2012, 16: 303-307. Go to PubMed...
    23. Sifaoui F, Arthur M, Rice L, et al. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob Agents Chemother 2001, 45: 2594-2597. Go to original source... Go to PubMed...
    24. Kolář M. Problematika vankomycin-rezistentních enterokoků. Klin Mikrobiol Inf Lék 2018, 24: 50-56.
    25. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother 2013, 68: 731-742. Go to original source... Go to PubMed...
    26. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988, 1: 57-58. Go to original source... Go to PubMed...
    27. Kolář M, Vágnerová I, Kohnová I. Záchyt vankomycin-rezistentních enterokoků ve Fakultní nemocnici v Olomouci. Klin Mikrobiol Inf Lék 1997, 3: 189-191.
    28. Barber M, Rozwadovska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet 1948, 255: 641-644. Go to original source... Go to PubMed...
    29. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150: 1545-1549. Go to original source... Go to PubMed...
    30. Peacock SJ, Paterson GK. Mechanisms of methicillin resistance in Staphylococcus aureus. Annu Rev Biochem 2015, 84: 577-601. Go to original source... Go to PubMed...
    31. Paterson GK, Harrison EM, Holmes MA. The emergence of mecC methicillin-resistant Staphylococcus aureus. Trends Microbiol 2014, 22: 42-47. Go to original source... Go to PubMed...
    32. Kolář M, Urbánek K, Vágnerová I, Koukalová D. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Therap 2006, 31: 67-72. Go to original source... Go to PubMed...
    33. Garneau-Tsodikova S, Labby KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Medchemcomm 2015, 7: 11-27. Go to original source... Go to PubMed...
    34. Kolář M.: Respirační infekce a jejich léčba. Maxdorf Jessenius, 2016.
    35. Jindrák V, Henyšová J, Vaniš V, Urbášková P, Litoš P. Rezistence Streptococcus pyogenes k erytromycinu jako regionální problém. Klin Mikrobiol Inf Lék 1999, 5: 237-243.
    36. Seppäla H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992, 326: 292-297. Go to original source... Go to PubMed...
    37. Seppäla H, Nissinen A, Yu Q, et al. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993, 32: 885-891. Go to original source... Go to PubMed...
    38. Kolář M, Urbánek K, Čekanová L, Koukalová D. Rezistence Streptococcus pyogenes k erytromycinu - závažný problém komunitních bakteriálních infekcí. Klin Farmakol Farmac 2001, 15: 13-16.
    39. Urbánek K, Kolář M, Čekanová L. Utilisation of macrolides and the development of Streptococcus pyogenes resistance to erythromycin. Pharm World Science 2005, 27: 104-107. Go to original source... Go to PubMed...
    40. Kolář M. Zásady antibiotické léčby. Rozhl Chir 2019, 98: 137-144. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.